ReviewDrug discovery today2025
Click chemistry for natural product-inspired covalent drug discovery.
Review in Drug discovery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metabolites, including primary and secondary metabolites, the latter often termed 'natural products' (NPs), offer a structurally rich source of scaffolds for drug discovery. Although many act through reversible binding, a notable subset exerts potent effects via covalent mechanisms, offering distinct advantages. Advances in click chemistry now enable modular incorporation of electrophilic warheads and bioorthogonal handles onto NP frameworks, facilitating the discovery of new covalent agents and the mapping of their biological activity. In this review, we highlight key classes of 'click electrophiles' and their integration into NP scaffolds, examine how click chemistry supports activity-based protein profiling (ABPP) of covalent NPs, and introduce clickable covalent metabolite mimetics (CoMMs) as a unifying framework for advancing inverse covalent drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.